Phase 1 trial evaluating MRG-106, a synthetic inhibitor of microRNA-155, in patients with cutaneous t-cell lymphoma (CTCL). Foss, F. M., Querfeld, C., Porcu, P., Kim, Y. H., Pacheco, T., Halwani, A., DeSimone, J., William, B. M., Seto, A. G., Ruckman, J., Landry, M. L., Jackson, A. L., Pestano, L. A., Dickinson, B. A., Sanseverino, M., Rodman, D. M., Rubin, P., Gordon, G., Marshall, W. S. AMER SOC CLINICAL ONCOLOGY. 2017

View details for DOI 10.1200/JCO.2017.35.15_suppl.7564

View details for Web of Science ID 000411932200019